{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Duration of response defined for all evaluable patients who have achieved a response as the date at which the patient's earliest best objective status is first noted to be a CR/CRi response to the earliest date progression is documented","groups":[{"description":"Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.","id":"OG000","title":"Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)"}],"populationDescription":"No patients responded, thus no patients were analyzed for this outcome measure. Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm.","reportingStatus":"POSTED","timeFrame":"Up to 17 months","title":"Duration of Response","type":"SECONDARY"}